Agios Pharmaceuticals, Inc. - SIC # 2830 -

Ticker Exchange SIC # Website Latest Ticker
AGIO Nasdaq 2830 www.agios.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Agios Pharmaceuticals, Inc.

Is Agios Pharmaceuticals (AGIO) Offering A Compelling Entry Point After Recent Share Price Swings - Jan 20th, 2026 10:11 am
Agios Pharmaceuticals, Inc. (AGIO): A Bull Case Theory - Jan 19th, 2026 3:19 pm
Agios Pharmaceuticals Touts 2026 Growth Plan at JPM: Acvezmi Launch, SCD Data, Expense Discipline - Jan 14th, 2026 11:16 am
Agios Pharmaceuticals outlines 2026 strategic priorities - Jan 13th, 2026 5:27 am
Agios Outlines 2026 Strategic Priorities and Key Milestones to Accelerate Rare Disease Portfolio Growth - Jan 12th, 2026 5:00 am
What Catalysts Are Rewriting The Story For Agios Pharmaceuticals (AGIO)? - Jan 8th, 2026 6:15 am
Agios to Present at the 44th Annual J.P. Morgan Healthcare Conference on January 14, 2026 - Jan 5th, 2026 5:00 am
Agios Pharmaceuticals (AGIO) Surges 18.6%: Is This an Indication of Further Gains? - Dec 26th, 2025 6:42 am
Agios (AGIO) Gets 18.6% Boost from Aqvesme OK - Dec 25th, 2025 8:39 am
Agios Pharmaceuticals price target raised to $34 from $32 at BofA - Dec 25th, 2025 4:05 am
Here's Why Shares in Agios Pharmaceuticals Popped Today - Dec 24th, 2025 10:23 am
Top Midday Stories: Apple's Cook Buys $3 Million in Nike Stock; OpenAI Explores Ads in ChatGPT; Sanofi-Dynavax $2.2 Billion Deal - Dec 24th, 2025 9:51 am
AGIO's Mitapivat Gets FDA Nod for Thalassemia Indication with REMS in Label - Dec 24th, 2025 9:05 am
Update: Agios Shares Rise After FDA Approves Aqvesme to Treat Anemia in Thalassemia Patients - Dec 24th, 2025 7:43 am
U.S. FDA Approves Agios’ AQVESME™ (mitapivat) for the Treatment of Anemia in Adults with Alpha- or Beta-Thalassemia - Dec 23rd, 2025 5:45 pm
Agios Awaits Pyrukynd Decision in Thalassemia as FDA Misses Due Date - Dec 9th, 2025 8:24 am
Agios Provides Update on U.S. sNDA for Mitapivat in Thalassemia - Dec 8th, 2025 5:00 am
How The Latest Trial And FDA Risk Shift The Story For Agios Pharmaceuticals - Dec 5th, 2025 8:07 pm
Sickle Cell Disease Market is Predicted to Exhibit Remarkable Growth at a CAGR of 22.1% During the Forecast Period (2025–2034) Across 6MM, Owing to the Increasing Prevalence, Awareness, and Advancements in Gene Therapies | DelveInsight - Dec 3rd, 2025 11:00 am
Agios Pharmaceuticals (AGIO) Upgraded After Mixed Sickle Cell Data and Pending Thalassemia Catalyst - Nov 25th, 2025 6:39 am